Oragenics to Participate at the World Vaccine Congress Washington 2022
18 Avril 2022 - 01:30PM
Business Wire
Company to showcase NT-CoV2-1, a
patient-friendly Covid vaccine candidate
Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the
“Company”), a biotech company dedicated to fighting infectious
diseases including coronavirus, today announced that Kimberly
Murphy, a member of the Company’s Board of Directors, will attend
the upcoming World Vaccine Congress Washington that will be held on
April 18-22 to showcase the Company’s lead product, NT-CoV2-1, an
intranasal vaccine candidate, and to pursue business development
opportunities.
The NT-CoV2-1 intranasal vaccine program approach is focused on
patient-friendly administration, reducing transmission through a
mucosal immune response, and to provide long-lasting protection. As
a recombinant protein and adjunctive vaccine, NT-CoV2-1 is
differentiated compared to live-attenuated intranasal vaccines
candidates that may cause greater side effects and harder to
produce. Animal models have demonstrated NT-CoV2-1 intranasal
formulation induced robust immune responses, lowering the viral
load below detection of the assay in the nasal passages and the
lungs. Currently, an IND-enabling GLP toxicology study is ongoing.
The Company expects to initiate a first-in-human Phase 1 trial in
previously vaccinated healthy adults this year.
Ms. Murphy joined Oragenic’s Board of Directors in 2020 and
actively provides vital insight to the Company’s strategic
corporate and development objectives. Formerly, she served in a
variety of vaccine-related leadership roles within GlaxoSmithKline
plc (GSK). While with GSK, Ms. Murphy led the global influenza
vaccine and pandemic preparedness businesses and was responsible
for the strategic and prelaunch planning for multiple
development-stage vaccines through commercialization. Earlier in
her career, she worked in commercialization roles within Merck and
Novartis Vaccines and Diagnostics Inc. Ms. Murphy currently serves
as a director of Blue Water Vaccines, Inc. (NASDAQ: BWV) and as a
director (chairperson) of Clarus Therapeutics Holdings Inc.
(NASDAQ: CRXT).
Please contact kmurphy@oragenics.com if you are interested in
meeting with Ms. Murphy at the World Vaccine Congress in Washington
D.C.
About Oragenics, Inc.
Oragenics, Inc. is a development-stage company dedicated to
fighting infectious diseases including coronaviruses and
multidrug-resistant organisms. Its lead product is NT-CoV2-1, an
intranasal vaccine candidate to prevent COVID-19 and variants of
the SARS-CoV-2 virus. The NT-CoV2-1 program leverages coronavirus
spike protein research licensed from the NIH and the NRC with a
focus on reducing viral transmission and offering a more
patient-friendly intranasal administration. Its lantibiotics
program features a novel class of antibiotics against bacteria that
have developed resistance to commercial antibiotics. For more
information about Oragenics, please visit www.oragenics.com.
Forward-Looking Statements
This communication contains “forward-looking statements” within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. These forward-looking
statements are based on management’s beliefs and assumptions and
information currently available. The words "believe," "expect,"
"anticipate," "intend," "estimate," "project" and similar
expressions that do not relate solely to historical matters
identify forward-looking statements. Investors should be cautious
in relying on forward-looking statements because they are subject
to a variety of risks, uncertainties, and other factors that could
cause actual results to differ materially from those expressed in
any such forward-looking statements. These factors include, but are
not limited to, the following: the Company’s ability to advance the
development of its vaccine candidate and lantibiotics candidate
under the timelines and in accord with the milestones it projects;
the Company’s ability to obtain funding, non-dilutive or otherwise,
for the development of the vaccine and lantibiotic product
candidates, whether through its own cash on hand, or another
alternative source; the regulatory application process, research
and development stages, and future clinical data and analysis
relating to vaccines and lantibiotics, including any meetings,
decisions by regulatory authorities, such as the FDA and
investigational review boards, whether favorable or unfavorable;
the potential application of our vaccine candidate to variants and
other coronaviruses; the Company’s ability to obtain, maintain and
enforce necessary patent and other intellectual property
protection; the nature of competition and development relating to
COVID-19 immunization and therapeutic treatments and demand for
vaccines and antibiotics; the Company’s expectations as to
administration, manufacturing, storage and distribution; other
potential adverse impacts due to the global COVID-19 pandemic, such
as delays in regulatory review, interruptions to manufacturers and
supply chains, adverse impacts on healthcare systems and disruption
of the global economy; and general economic and market conditions
and risks, as well as other uncertainties described in our filings
with the U.S. Securities and Exchange Commission. All information
set forth in this press release is as of the date hereof. You
should consider these factors in evaluating the forward-looking
statements included in this press release and not place undue
reliance on such statements. We do not assume any obligation to
publicly provide revisions or updates to any forward-looking
statements, whether as a result of new information, future
developments or otherwise, should circumstances change, except as
otherwise required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220418005243/en/
Oragenics, Inc. Michael Sullivan, Chief Financial Officer
813-286-7900 msullivan@oragenics.com
Or
LHA Investor Relations Tirth T. Patel 212-201-6614
tpatel@lhai.com
Oragenics (AMEX:OGEN)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024
Oragenics (AMEX:OGEN)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024